At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Market Closed 11-01 16:00:00 EDT
1.54
-0.08
-4.94%
盘后1.46
-0.08-5.19%
19:55 EDT
High1.72
Low1.42
Vol604.97K
Open1.63
D1 Closing1.62
Amplitude18.52%
Mkt Cap66.65M
Tradable Cap53.29M
Total Shares43.28M
T/O937.68K
T/O Rate1.75%
Tradable Shares34.60M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Quince Therapeutics Initiated at Buy by Rodman & Renshaw
Quince Therapeutics Announces the Lancet Neurology Publication of Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (a-T)
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.